United Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- United Therapeutics's estimated annual revenue is currently $1.7B per year.
- United Therapeutics's estimated revenue per employee is $1,663,327
- United Therapeutics's total funding is $70M.
- United Therapeutics's current valuation is $9.6B. (January 2022)
Employee Data
- United Therapeutics has 998 Employees.
United Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP, Operational Technology | Reveal Email/Phone |
2 | Associate VP, Medical Device Operations | Reveal Email/Phone |
3 | Sr. VP Sales & Marketing | Reveal Email/Phone |
4 | Associate VP, Global Regulatory Affairs | Reveal Email/Phone |
5 | Sr. VP & Chief Medical Officer, Lung Biotechnology, PBC | Reveal Email/Phone |
6 | Associate VP Managed Markets and Reimbursement | Reveal Email/Phone |
7 | VP, Associate General Counsel, Market Access | Reveal Email/Phone |
8 | VP Business and Legal Affairs | Reveal Email/Phone |
9 | VP, E-Aviation - Organ Delivery Systems | Reveal Email/Phone |
10 | VP Global Supply Chain and Alliance Management | Reveal Email/Phone |
United Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7M | 35 | -3% | N/A | N/A |
#2 | $7.2M | 36 | -5% | N/A | N/A |
#3 | $10.5M | 52 | -9% | N/A | N/A |
#4 | $344.1M | 1712 | 9% | N/A | N/A |
#5 | $27.5M | 137 | 6% | N/A | N/A |
#6 | $107.3M | 534 | 9% | N/A | N/A |
#7 | $12.9M | 64 | 28% | N/A | N/A |
#8 | $31.6M | 157 | 1% | N/A | N/A |
#9 | $31.4M | 156 | 7% | N/A | N/A |
#10 | $11.5M | 57 | 30% | N/A | N/A |
What Is United Therapeutics?
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine.
keywords:N/A
$70M
Total Funding
998
Number of Employees
$1.7B
Revenue (est)
N/A
Employee Growth %
$9.6B
Valuation
N/A
Accelerator
United Therapeutics News
United Therapeutics Hosts Community Meeting on Initial Concept for New Office Building. Mike Diegel | April 21, 2022 | Categories Silver Spring.
In 2020, United Therapeutics (Nasdaq: UTHR) which has a headquarters in the Triangle sued Liquidia for alleged patent infringement...
United Therapeutics Announces the Publication of Tyvaso DPI BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021 grew 23% year over year to $446.5 million, compa ...
Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI™ NDA under review with FDA action expected in October 2021 SILVER SPRING, MD. and RESEARCH TRIANGLE PARK, N.C., August 4, 2021: United Therapeutics Cor ...
Other Companies in Silver Spring
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $467.1M | 1011 | 9% | N/A |
#2 | $75M | 1532 | 9% | N/A |
#3 | $75M | 2133 | 51% | N/A |
#4 | $770.3M | 2620 | 6% | N/A |
#5 | $1389.9M | 3677 | 6% | N/A |